Pei-Yun Hung

Title: Pei-Yun Hung: Innovator in Cancer Treatment

Pei-Yun Hung is a notable inventor based in Taipei, Taiwan. She has made significant contributions to the field of cancer treatment through her innovative research and development of histone deacetylases (HDACs) inhibitors. Her work focuses on creating compounds that can effectively target and treat various types of cancer.

Latest Patents

Pei-Yun Hung holds 1 patent related to histone deacetylases (HDACs) inhibitors. The patent discloses a structural formula for these inhibitors, which includes a benzene ring and a cyclohexane ring, both of which may be substituted. The HDACs inhibitors developed by Hung demonstrate cytotoxicity against various cancer cell lines. They are particularly useful for treating tumors associated with the deregulation of histone deacetylases activity. This includes applications for glioma, breast cancer, colon cancer, lung cancer, and several other malignancies.

Career Highlights

Pei-Yun Hung is affiliated with Annji Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her work has positioned her as a key figure in the pharmaceutical industry, particularly in the area of cancer therapeutics.

Collaborations

Throughout her career, Pei-Yun Hung has collaborated with esteemed colleagues such as Ji-Wang Chern and Chao-Wu Yu. These collaborations have further enhanced her research capabilities and contributed to the advancement of cancer treatment options.

Conclusion

Pei-Yun Hung's innovative work in developing HDACs inhibitors represents a significant advancement in cancer treatment. Her contributions are vital in the ongoing fight against various forms of cancer, showcasing the importance of research and innovation in the medical field.